The cancer anorexia/weight loss syndrome: Therapeutic challenges

Current Oncology Reports

Volumn 7, Issue 4, 2005, Pages 271-276

  Giordano, Karin F ^a   Jatoi, Aminah ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; APPETITE STIMULANT; BORTEZOMIB; CORTICOSTEROID; CREATINE; CYPROHEPTADINE; DRONABINOL; ETANERCEPT; FLUOXYMESTERONE; GESTAGEN; HYDRAZINE SULFATE; ICOSAPENTAENOIC ACID; INFLIXIMAB; MEGESTROL ACETATE; MELATONIN; OXANDROLONE; PENTOXIFYLLINE; PLACEBO; PROTEASOME; PROTEOGLYCAN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

ANOREXIA; APPETITE; BODY COMPOSITION; BODY WEIGHT DISORDER; CACHEXIA; CANCER SURVIVAL; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIETARY INTAKE; ENERGY EXPENDITURE; EVIDENCE BASED MEDICINE; HUMAN; INTERPERSONAL COMMUNICATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; META ANALYSIS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COUNSELING; PREVALENCE; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REST; REVIEW; SYSTEMATIC REVIEW; THROMBOPHLEBITIS; TREATMENT OUTCOME; WEIGHT REDUCTION; NEOPLASM; PHYSIOLOGY; SIGNAL TRANSDUCTION; SYNDROME;

ANOREXIA; CLINICAL TRIALS; HUMANS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; SYNDROME; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN; WEIGHT LOSS;

EID: 23344454966     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0050-9     Document Type: Review

References (33)

1. Pestalozzi BC: Looking at the dying patient: the Ferdinand Hodler paintings of Valentine Gode-Darel. J Clin Oncol 2002, 20:1948-1959.
2. DeWys WD, Begg C, Lavin PT, et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980, 69:491-497.
3. Ross PJ, Ashley S, Norton A, et al.: Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004, 90:1905-1911.
4. Loprinzi CL, Laurie JA, Wieand HS, et al.: Prospective evaluation of prognostic variables from patient-completed questionnaires. J Clin Oncol 1994, 12:601-607.
5. Sarhill N, Mahmoud F, Walsh D, et al.: Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer 2003, 11:652-659.
6. Finkelstein DM, Cassileth BR, Bonomi PD, et al.: A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1989, 11:630-633.
7. Socinski MA, Zhang C, Herndon JE, et al.: Combined modality trials of the Cancer and Leukemia Group B in stage III non-small cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 2004, 15:1033-1041.
8. Walsh D, Rybicki L, Nelson KA, Donnelly S: Symptoms and prognosis in advanced cancer. Support Care Cancer 2002, 10:385-388.
9. Cohn SH, Gartenhaus W, Sawitsky A, et al.: Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium, and water. Metabol Clin Exp 1981, 30:222-229.
10. Kotler DP, Tierney AR, Wang J, Pierson RN: Magnitude of body cell mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutrition 1989, 50:444-7.
11. Keys A, Brozek J, Henschel A, et al.: The Biology of Human Starvation. St. Paul, MN: The University of Minnesota Press, 1950.
12. Jatoi A, Daly BD, Hughes VA, et al.: Do patients with metastatic non-small cell lung cancer demonstrate altered resting energy expenditure? Ann Thorac Surg 2001, 72:348-351.
13. Baracos VE, DeVivo C, Hoyle DH, Goldberg AL: Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol 1995, 268:E996-E1006.
14. Lazarus DD, Destree AT, Mazzola LM, et al.: A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway. Am J Physiol 1999, 277:E332-E341.
15. Bossola M, Muscaritoli M, Costelli P, et al.: Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 2003, 237:384-389.
16. Jatoi A, Alberts S, Foster N, et al.: Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. Support Care Cancer, in press.
17. Jatoi A, Egner J, Loprinzi CL, et al.: Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. Support Care Cancer 2004, 12:640-644.
18. Llovera M, Garda-Martinez C, Lopez-Soriano J, et al.: Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol 1998, 142:183-189.
19. Torelli GF, Meguid MM, Moldawer LL, et al.: Use of recombinant soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol1999, 277 (3 Pt 2):R850-R855.
20. Langen RC, Van Der Velden JL, et al.: Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J 2004, 18:227-237.
21. Todorov P, Cariuk P, McDEvitt T, et al.: Characterization of a cancer cachectic factor. Nature 1996, 379:739-742.
22. Ovesen L, Allingstrup, L, Hannibal J, et al.: Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 1993, 11:2043-2049.
23. Ravasco P, Montiero-Grillo I, Vidal PM, Camilo ME: Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 2005, 23:1-8.
24. Loprinzi CL, Ellison NM, Schaid DJ, et al.: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990, 82:1127-1132.
25. Goldberg RM, Loprinzi CL, Mailliard JA, et al.: Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double blind placebo-controlled trial. J Clin Oncol 1995, 13:2856-2859.
26. Loprinzi CL, Kugler JW, Sloan JA, et al.: Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999, 17:3299-3306.
27. Kardinal CG, Loprinzi CL, Schaid DJ, et al.: A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990, 65:2657-2662.
28. Loprinzi CL, Goldberg RM, Su JO, et al.: Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small cell lung cancer. J Clin Oncol 1994, 12:1126-1129.
29. Jatoi A, Windschitl HE, Loprinzi CL, et al.: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia. J Clin Oncol 2002, 20:567-573.
30. Jatoi A, Rowland K, Loprinzi CL, et al.: An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting. J Clin Oncol 2004, 22:2469-2476.
31. Jatoi A, Kumar S, Sloan J, Nguyen PL: On appetite and its loss. J Clin Oncol 2000, 18:2930-2932.
32. Loprinzi CL, Bernath AM, Schaid DJ, et al.: Phase III Evaluation of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Oncology 1994, 51(Suppl 1):2-7.
33. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974, 33: 1607-1609.